Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, TDS, FVT

Fuse Oncology Unveils FuseDocs: Newest RadOnc Solution for Streamlining Clinical Documentation for Radiation Oncologists

Fuse also announces Syntyant, a new interoperable platform for RadOnc providing seamless connectivity among diverse healthcare technologies to accelerate delivery of care

BOONE, N.C., Sept. 29, 2023 /PRNewswire/ -- Fuse Oncology (Fuse) a trailblazing leader in radiation oncology software solutions, unveils their latest pioneering product, FuseDocs, today. This groundbreaking software leverages generative artificial intelligence (AI) to transform radiation oncology documentation, allowing oncologists to refocus their energies on patient care.

FuseDocs leverages generative AI to transform RadOnc documentation allowing oncologists to refocus on patient care.

FuseDocs automatically and effortlessly generates clinical documentation, drastically reducing the time needed to produce essential records. By accurately generating the correct documents at the right time, human errors are reduced while ensuring compliance with regulatory requirements.

President of Radiation Oncology Associates, PC, and the emeritus Chairman and Medical Director of the Department for Advanced Radiation Oncology and Proton Therapy for Inova Schar Cancer Institute Gopal K. Bajaj, MD MBA FASTRO said, "Fuse is not only introducing a product?they are ushering in a new era of efficiency and innovation in radiation oncology. Their mission is clearly being realized?to empower radiation oncologists to provide the best care possible, and FuseDocs is a significant step in that direction."

FuseDocs represents a pivotal advancement in the field of radiation oncology. By replacing template-based approaches with fully automated documentation that leverages generative AI, the administrative burden is significantly reduced?empowering radiation oncologists to focus on what truly matters? providing exceptional patient care.

"We're excited to introduce FuseDocs to the radiation oncology community at ASTRO," said Fuse CEO James Bauler. "Our software leverages generative AI to create unprecedented efficiencies, enabling radiation oncologists to invest their time and talent in patient care, unburdened by administrative tasks. FuseDocs moves RadOnc one step closer to delivering care at the speed of the patient."

FuseDocs builds upon the success of Fuse's existing product, S!GNAL, which is creating a RadOnc world where workflows are automatically monitored for consistent adherence. A simple secure dashboard provides real-time feedback to assist healthcare systems and RadOnc clinics discover revenue opportunities by detecting missing documentation, incomplete tasks and errors in charge capture.

Along with FuseDocs, Fuse also unveiled today their interoperable platform for RadOnc, Syntyant, which provides seamless connectivity among diverse healthcare technologies including EMR, OIS, and planning systems to accelerate delivery of care.

Fuse will be at booth #1618 at the ASTRO conference from October 1-4 to showcase their suite of products and offer live FuseDocs demos.

About Fuse Oncology 

Fuse Oncology delivers SaaS solutions that break down healthcare workflow and data silos to create a seamless experience for clinicians in radiation oncology. By placing the broader electronic medical record system at the center of the architecture, Fuse eliminates duplicative and inefficient efforts to enable a future where oncology care moves at the speed of the patient. For more information about FuseDocs and its features, visit FuseOnc.com. Stay updated on our latest developments by following us on LinkedIn @fuseoncology.

SOURCE Fuse Oncology, Inc.

These press releases may also interest you

at 12:35
PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights to RO7117997....

at 12:30
Health Data Movers, a "Best in KLAS" healthcare technology services firm, is thrilled to announce its strategic partnership with Workday as a certified Workday Advisory Services Partner. This collaboration marks a significant milestone in Health Data...

at 12:30
The "DUPIXENT Drug Insight and Market Forecast - 2032" report has been added to  ResearchAndMarkets.com's offering. DUPIXENT's potential as a game-changer extends further with its invention through Regeneron's proprietary VelocImmune technology....

at 12:27
The Alzheimer's Association is saddened by the death of former Supreme Court Justice Sandra Day O'Connor. A trailblazer and transparent leader throughout her life, Justice O'Connor bravely shared her diagnosis of "dementia, probably Alzheimer's...

at 12:16
The Bone Health and Osteoporosis Foundation (BHOF) is pleased to announce the 2023 recipients of our national award to recognize Members of Congress who have demonstrated outstanding leadership, advocacy, and commitment to protect and improve the...

at 12:15
The "mRNA Platform Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F" report has been added to ResearchAndMarkets.com's offering. Global mRNA Platform Market is anticipated to witness an impressive growth to 2028 The mRNA...

News published on and distributed by: